J&J expects 10-plus new drug applications by 2017

May 23, 2013 by Linda A. Johnson

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during a review of the health care giant's medicine business.

The , a chemical cousin of the powerful anesthetic ketamine, appears to bring relief from crippling depression in just a day—rather than the four to eight weeks needed for existing pills, which don't work for many patients.

The pain treatment, while in earlier stages of testing, is not addictive and could replace widely used—and abused—opioid painkillers such as Oxycontin that cause harsh side effects and many fatal overdoses.

J&J, which makes everything from baby shampoo and Tylenol to biologic drugs and medical devices, has seen its revenue rebound after a rare decline in 2009, thanks to a surge of 11 new medicines launched since then. Unlike most drugmakers, J&J is well past its worst stretch of its big prescription drugs losing patent protection and seeing their sales slashed by cheaper generic competition.

And now the company says it plans by 2017 to apply for approval of 11 new medicines in the U.S. and Europe, plus a polio vaccine for other parts of the world and 25 variations of existing drugs.

"Our focus is now on enhancing our pipeline to deliver the next wave of growth," Joaquin Duato, one of two chairman of J&J's worldwide prescription drug business, told analysts and journalists at the daylong meeting.

Like its rivals, the company says it is focusing on conditions that lack adequate treatments, as well as expanding sales in emerging markets such as China and India.

J&J's 11 experimental drugs, now in mid- or late-stage patient testing, include a potential hepatitis C treatment being reviewed by regulators, a version of its Invega Sustenna schizophrenia shot designed to last three months, drugs for three types of cancer and new vaccines for flu and rabies.

Another of the 11 drugs is esketamine, which is chemically related to ketamine, an anesthetic sometimes abused at raves for the high and hallucinations it can produce.

J&J this year started mid-stage patient testing of an inhaled, low-dose version of esketamine for patients not helped by other antidepressants. Assuming it's approved, J&J is planning to have it administered in doctor's offices and clinics, but not distributed through pharmacies—to limit the potential for abuse, said Dr. Husseini Manji, head of neuroscience research.

He said J&J is also testing variations including a pill version and using esketamine to treat bipolar disorder, adding that doctors and government mental health experts have high hopes for what could be "the biggest breakthrough in psychiatry in 40 years."

That's needed because depression is one of the top causes of disability worldwide and leads to more than 38,000 suicides a year— just in the U.S. Current treatments only resolve depression in about a third of patients.

The promising pain drug, fulranumab, is currently being tested in patients with osteoarthritis, the joint pains common in older folks from years of wear and tear, and in patients with pain from nerve damage caused by diabetes. It also could be tested for back or other pain types.

Manji said it could be a big advance over today's options. Those are mainly anti-inflammatory pain relievers such as naproxen that aren't always effective and addictive narcotic painkillers that are responsible for pill mills, crime rings and thousands of overdoses.

If approved, it could usher in a "post-opioid era," Manji said.

J&J said it's continuing research on multiple ways to attack Alzheimer's disease, and downplayed the failure last year of one drug it's been developing with Pfizer Inc.

Johnson & Johnson also is researching new treatments for heart disease, immune disorders and diabetes.

Executives noted the company's drug business is growing fastest among the top 10 drugmakers in the key markets of the U.S., Europe and Japan.

The 11 new products it's launched since 2009 brought in 17 percent of total pharmaceutical sales last year, up from 9 percent in 2011. Those products include Zytiga for prostate cancer, anti-clotting drug Xarelto, Incivo for hepatitis C and J&J's first diabetes treatment, Invokana.

Explore further: US OKs first-of-its-kind diabetes drug (Update)

Related Stories

US OKs first-of-its-kind diabetes drug (Update)

March 29, 2013
The U.S. Food and Drug Administration on Friday approved a first-of-its-kind diabetes drug from Johnson & Johnson that uses a new method to lower blood sugar—flushing it out in patients' urine.

Fearing abuse, US blocks generic OxyContin (Update)

April 16, 2013
U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.

FDA links once-promising pain drugs to bone decay

March 8, 2012
Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental arthritis drugs that have been sidelined by safety concerns for nearly two years.

US panel backs novel diabetes pill from J&J (Update)

January 10, 2013
A panel of U.S. health experts ruled Thursday that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked over the long term.

Pfizer Q4 net jumps on sale of nutrition business

January 29, 2013
Pfizer Inc.'s fourth-quarter profit more than quadrupled, despite competition from generic drugs hurting sales of Lipitor and other medicines, because of a $4.8 billion gain from selling its nutrition business. The drugmaker's ...

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.